Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo

NCT00088036 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00088036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00088036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2004
Completion date
January 31, 2006
Enrollment
450
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

borderline personality disorder